 <h1>Riabni Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>rituximab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about rituximab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Riabni.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to rituximab: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Fatal infusion-related reactions may occur within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with the first infusion. Monitor patients and discontinue rituximab infusion after severe reactions. Severe and potentially fatal mucocutaneous reactions can occur. Reactivation of hepatitis B virus (HBV) may occur; in some cases, it results in fulminant hepatitis, hepatic failure, or death. Screen patients for HBV infection prior to treatment. Progressive multifocal leukoencephalopathy (PML) and death can also occur.</p><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Warning: Fatal Infusion Reactions, Severe Mucocutaneous Reactions, Hepatitis B Virus Reactivation, and Progressive Multifocal LeukoencephalopathyFatal infusion-related reactions within 24 hours of rituximab infusion; approximately 80% of fatal infusion reactions occurred with first infusion. Monitor patients and discontinue rituximab-pvvr infusion for severe reactions.Severe mucocutaneous reactions, some with fatal outcomesHepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and deathProgressive multifocal leukoencephalopathy (PML) resulting in death</p><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Fatal infusion reactions may occur within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with the first infusion. Monitor patients and discontinue rituximab-abbs infusion for severe reactions. Severe and potentially fatal mucocutaneous reactions can occur. Reactivation of hepatitis B virus (HBV) may occur with some cases resulting in fulminant hepatitis, hepatic failure, or death. Screen patients for HBV infection prior to treatment. Progressive multifocal leukoencephalopathy (PML), including fatal PML, can also occur.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, rituximab (the active ingredient contained in Riabni) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking rituximab:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>burning or stinging of the skin</li>
<li>chest pain</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>ear congestion</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>headache</li>
<li>hives or welts, itching, rash</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>nervousness</li>
<li>noisy breathing</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>painful cold sores or blisters on the lips, nose, eyes, or genitals</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>seizures</li>
<li>slow or fast heartbeat</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>stomach pain</li>
<li>stuffy or runny nose</li>
<li>sweating</li>
<li>swelling of the tongue or throat</li>
<li>swollen glands</li>
<li>tightness of the chest</li>
<li>tingling of the hands or feet</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>blisters on the trunk, scalp, or other areas</li>
<li>burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feeling</li>
<li>decreased frequency and amount of urine</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>irregular heartbeat</li>
<li>irritability</li>
<li>joint or muscle pain</li>
<li>loss of appetite</li>
<li>loss of interest or pleasure</li>
<li>lump or growth on the skin</li>
<li>muscle cramp, pain, or stiffness</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>painful blisters on the trunk of the body</li>
<li>pain or redness at the injection site</li>
<li>pain, swelling, or redness in the joints</li>
<li>pounding or irregular heartbeat or pulse</li>
<li>red skin lesions, often with a purple center</li>
<li>red, itchy lining of the eye</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>stabbing pain</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blue-yellow color blindness</li>
<li>blurred vision or other change in vision</li>
<li>burning or stinging of the skin</li>
<li>decreased vision</li>
<li>dilated neck veins</li>
<li>dry cough</li>
<li>extreme tiredness or weakness</li>
<li>eye pain, tearing</li>
<li>feeling of discomfort, illness, or weakness</li>
<li>irregular breathing</li>
<li>nosebleed</li>
<li>painful cold sores or blisters on the lips, nose, eyes, or genitals</li>
<li>sensitivity of the eye to light</li>
<li>severe abdominal or stomach pain</li>
<li>severe vomiting, sometimes with blood</li>
<li>sores, welts, or blisters</li>
<li>stomach cramps</li>
<li>swelling, stiffness, redness, or warmth around many joints</li>
<li>swollen lymph glands</li>
<li>vision loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of rituximab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Fear</li>
<li>hair loss</li>
<li>lack or loss of strength</li>
<li>night sweats</li>
<li>thinning of the hair</li>
<li>throat irritation</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Agitation or anxiety</li>
<li>bone pain</li>
<li>burning, dry, or itching eyes</li>
<li>change in taste</li>
<li>discharge, excessive tearing</li>
<li>dry eyes</li>
<li>excessive muscle tone</li>
<li>feeling of constant movement of self or surroundings</li>
<li>heartburn</li>
<li>increase in body movements</li>
<li>lightheadedness</li>
<li>muscle tension</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>sensation of spinning</li>
<li>sleepiness</li>
<li>swelling of the stomach</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rituximab: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (10%)</p>
<p><b>Common</b> (1% to 10%): Hypertension, orthostatic hypotension, myocardial infarction, arrhythmia, atrial fibrillation, tachycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): Left ventricular failure, supraventricular tachycardia, ventricular tachycardia, angina, myocardial ischemia, bradycardia</p>
<p><b>Very rare</b> (less than 0.01%): Heart failure, vasculitis (predominately cutaneous), leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Night sweats (15%), rash (15%), pruritus (14%), angioedema (11%), alopecia</p>
<p><b>Common</b> (1% to 10%): Flushing, urticaria, skin disorder</p>
<p><b>Very rare</b> (less than 0.01%): Severe bullous skin reactions, Stevens-Johnson Syndrome, toxic epidermal necrolysis (Lyell's Syndrome) </p>
<p><b>Postmarketing reports</b>: Severe mucocutaneous reactions<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (23%), abdominal pain (14%), diarrhea (10%), vomiting (10%)</p>
<p><b>Common</b> (1% to 10%): Throat irritation, dysphagia, stomatitis, constipation, dyspepsia, anorexia</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal enlargement</p>
<p><b>Frequency not reported</b>: GI perforation</p>
<p><b>Postmarketing reports</b>: Bowel obstruction<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (48%), leukopenia (14%), neutropenia (14%), thrombocytopenia (12%)</p>
<p><b>Common</b> (1% to 10%): Blood lactate dehydrogenase (LDH) increased, pancytopenia, granulocytopenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Anemia, coagulation disorders, aplastic anemia, hemolytic anemia, lymphadenopathy, transient aplastic anemia, hemolytic anemia </p>
<p><b>Postmarketing reports</b>: Late neutropenia, marrow hypoplasia, Grade 3 to 4 prolonged or late-onset neutropenia, hyperviscosity syndrome in Waldenstrom's macroglobulinemia, prolonged hypogammaglobulinemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (13%)</p>
<p><b>Frequency not reported</b>: Hepatitis B reactivation with fulminant hepatitis, hepatic failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity</p>
<p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis </p>
<p><b>Very rare</b> (less than 0.01%): Tumor lysis syndrome, cytokine release syndrome, serum sickness<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (bacterial, viral) (31%)</p>
<p><b>Common</b> (1% to 10%): Sepsis, febrile infection, herpes zoster, fungal infections, infections of unknown etiology, acute bronchitis, sinusitis</p>
<p><b>Rare</b> (less than 0.1%): Serious viral infections </p>
<p><b>Postmarketing reports</b>: Lupus-like syndrome, serum sickness, increase in fatal infections in HIV-associated lymphoma, increased incidence of Grade 3 and 4 infections<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Acute infusion reactions (e.g., pain, fever, chills, rigors, pruritus, urticaria/rash, angioedema, sneezing, throat irritation, cough, and/or bronchospasm, with or without associated hypotension or hypertension) (27%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypophosphatemia (12%)</p>
<p><b>Common</b> (1% to 10%): Hyperglycemia, peripheral edema, hyperuricemia, weight decrease, peripheral edema, face edema, increased LDH, hypocalcemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (10%), myalgia (10%), arthralgia (10%)</p>
<p><b>Common</b> (1% to 10%): Neck pain, hypertonia</p>
<p><b>Frequency not reported</b>: Polyarticular arthritis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (19%), dizziness (10%)</p>
<p><b>Common</b> (1% to 10%): Pyrexia, paresthesia, hypoesthesia</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysgeusia</p>
<p><b>Postmarketing reports</b>: Posterior reversible encephalopathy syndrome (PRES)/reversible posterior leukoencephalopathy syndrome (RPLS)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Lacrimation disorder, conjunctivitis</p>
<p><b>Very rare</b> (less than 0.01%): Severe vision loss</p>
<p><b>Postmarketing reports</b>: Uveitis, optic neuritis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Postmarketing reports</b>: Disease progression of Kaposi's sarcoma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (53%), chills (33%), asthenia (26%), fatigue (13%), pain (12%)</p>
<p><b>Common</b> (1% to 10%): Migraine, asthenia, tinnitus, ear pain, tumor pain, flushing, malaise, cold syndrome, shivering, multi-organ failure</p>
<p><b>Very rare</b> (less than 0.01%): Hearing loss<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, depression, nervousness, agitation, insomnia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very rare</b> (less than 0.01%): Renal failure<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (13%), rhinitis (12%), epistaxis (11%), dyspnea (10%), bronchitis</p>
<p><b>Common</b> (1% to 10%): Bronchospasm, sinusitis, pneumonia, chest pain </p>
<p><b>Uncommon</b> (0.1% to 1%): Upper respiratory tract infection, asthma, bronchiolitis obliterans (fatal), lung disorder, hypoxia</p>
<p><b>Rare</b> (0.01% to 0.1%): Interstitial lung disease </p>
<p><b>Very rare</b> (less than 0.01%): Respiratory failure</p>
<p><b>Frequency not reported</b>: Lung infiltration</p>
<p><b>Postmarketing reports</b>: Pleuritis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Rituxan (rituximab)." Genentech, South San Francisco, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the new drugs for the treatment of rheumatoid arthritis (RA)?</li>
<li>How many biosimilars have been approved in the United States?</li>
<li>What is the difference between Truxima and Rituxan?</li>
<li>Are lung nodules common after Bendeka &amp; Rituxan therapy?</li>
<li>What is the difference between Rituxan and Rituxan Hycela?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Riabni (rituximab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: CD20 monoclonal antibodies</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Rituxan, Truxima, Ruxience</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Lymphocytic Leukemia</li>
<li>Diffuse Large B-Cell Lymphoma</li>
<li>Follicular Lymphoma</li>
<li>Granulomatosis with Polyangiitis</li>
<li>Microscopic polyangiitis</li>
<li>Non-Hodgkin's Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rituximab: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (10%)</p><p><b>Common</b> (1% to 10%): Hypertension, orthostatic hypotension, myocardial infarction, arrhythmia, atrial fibrillation, tachycardia</p><p><b>Uncommon</b> (0.1% to 1%): Left ventricular failure, supraventricular tachycardia, ventricular tachycardia, angina, myocardial ischemia, bradycardia</p><p><b>Very rare</b> (less than 0.01%): Heart failure, vasculitis (predominately cutaneous), leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Night sweats (15%), rash (15%), pruritus (14%), angioedema (11%), alopecia</p><p><b>Common</b> (1% to 10%): Flushing, urticaria, skin disorder</p><p><b>Very rare</b> (less than 0.01%): Severe bullous skin reactions, Stevens-Johnson Syndrome, toxic epidermal necrolysis (Lyell's Syndrome) </p><p><b>Postmarketing reports</b>: Severe mucocutaneous reactions<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (23%), abdominal pain (14%), diarrhea (10%), vomiting (10%)</p><p><b>Common</b> (1% to 10%): Throat irritation, dysphagia, stomatitis, constipation, dyspepsia, anorexia</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal enlargement</p><p><b>Frequency not reported</b>: GI perforation</p><p><b>Postmarketing reports</b>: Bowel obstruction<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (48%), leukopenia (14%), neutropenia (14%), thrombocytopenia (12%)</p><p><b>Common</b> (1% to 10%): Blood lactate dehydrogenase (LDH) increased, pancytopenia, granulocytopenia</p><p><b>Uncommon</b> (0.1% to 1%): Anemia, coagulation disorders, aplastic anemia, hemolytic anemia, lymphadenopathy, transient aplastic anemia, hemolytic anemia </p><p><b>Postmarketing reports</b>: Late neutropenia, marrow hypoplasia, Grade 3 to 4 prolonged or late-onset neutropenia, hyperviscosity syndrome in Waldenstrom's macroglobulinemia, prolonged hypogammaglobulinemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (13%)</p><p><b>Frequency not reported</b>: Hepatitis B reactivation with fulminant hepatitis, hepatic failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis </p><p><b>Very rare</b> (less than 0.01%): Tumor lysis syndrome, cytokine release syndrome, serum sickness<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (bacterial, viral) (31%)</p><p><b>Common</b> (1% to 10%): Sepsis, febrile infection, herpes zoster, fungal infections, infections of unknown etiology, acute bronchitis, sinusitis</p><p><b>Rare</b> (less than 0.1%): Serious viral infections </p><p><b>Postmarketing reports</b>: Lupus-like syndrome, serum sickness, increase in fatal infections in HIV-associated lymphoma, increased incidence of Grade 3 and 4 infections<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Acute infusion reactions (e.g., pain, fever, chills, rigors, pruritus, urticaria/rash, angioedema, sneezing, throat irritation, cough, and/or bronchospasm, with or without associated hypotension or hypertension) (27%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypophosphatemia (12%)</p><p><b>Common</b> (1% to 10%): Hyperglycemia, peripheral edema, hyperuricemia, weight decrease, peripheral edema, face edema, increased LDH, hypocalcemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (10%), myalgia (10%), arthralgia (10%)</p><p><b>Common</b> (1% to 10%): Neck pain, hypertonia</p><p><b>Frequency not reported</b>: Polyarticular arthritis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (19%), dizziness (10%)</p><p><b>Common</b> (1% to 10%): Pyrexia, paresthesia, hypoesthesia</p><p><b>Uncommon</b> (0.1% to 1%): Dysgeusia</p><p><b>Postmarketing reports</b>: Posterior reversible encephalopathy syndrome (PRES)/reversible posterior leukoencephalopathy syndrome (RPLS)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Lacrimation disorder, conjunctivitis</p><p><b>Very rare</b> (less than 0.01%): Severe vision loss</p><p><b>Postmarketing reports</b>: Uveitis, optic neuritis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Postmarketing reports</b>: Disease progression of Kaposi's sarcoma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (53%), chills (33%), asthenia (26%), fatigue (13%), pain (12%)</p><p><b>Common</b> (1% to 10%): Migraine, asthenia, tinnitus, ear pain, tumor pain, flushing, malaise, cold syndrome, shivering, multi-organ failure</p><p><b>Very rare</b> (less than 0.01%): Hearing loss<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, depression, nervousness, agitation, insomnia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very rare</b> (less than 0.01%): Renal failure<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (13%), rhinitis (12%), epistaxis (11%), dyspnea (10%), bronchitis</p><p><b>Common</b> (1% to 10%): Bronchospasm, sinusitis, pneumonia, chest pain </p><p><b>Uncommon</b> (0.1% to 1%): Upper respiratory tract infection, asthma, bronchiolitis obliterans (fatal), lung disorder, hypoxia</p><p><b>Rare</b> (0.01% to 0.1%): Interstitial lung disease </p><p><b>Very rare</b> (less than 0.01%): Respiratory failure</p><p><b>Frequency not reported</b>: Lung infiltration</p><p><b>Postmarketing reports</b>: Pleuritis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Rituxan (rituximab)." Genentech, South San Francisco, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs for the treatment of rheumatoid arthritis (RA)?</li>
<li>How many biosimilars have been approved in the United States?</li>
<li>What is the difference between Truxima and Rituxan?</li>
<li>Are lung nodules common after Bendeka &amp; Rituxan therapy?</li>
<li>What is the difference between Rituxan and Rituxan Hycela?</li>
</ul><h2>More about Riabni (rituximab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: CD20 monoclonal antibodies</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Lymphocytic Leukemia</li>
<li>Diffuse Large B-Cell Lymphoma</li>
<li>Follicular Lymphoma</li>
<li>Granulomatosis with Polyangiitis</li>
<li>Microscopic polyangiitis</li>
<li>Non-Hodgkin's Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>